Celularity Signs Exclusive Deal with Vesalius Longevity Labs

With FDA scrutiny of imported peptide APIs intensifying and the Pharmacy Compounding Advisory Committee (PCAC) review still unresolved, Celularity Inc. has moved to position its Florham Park, New Jersey facility as a domestic finish-manufacturing platform for Vesalius Longevity Labs' Peptual-branded active pharmaceutical ingredients.

Under the exclusive agreement, Celularity will perform downstream purification, processing, analytical testing, and final-stage manufacturing using supplier-provided bulk peptide material. The scope is structured to satisfy cGMP requirements, with defined product specifications, documented sourcing, and lot-level traceability built into the process design from the outset. Celularity's existing biologics manufacturing infrastructure and technical personnel provide the operational baseline for extending those capabilities into peptide API production.

The regulatory context is explicit in both parties' rationale. If the FDA, following PCAC recommendations, adds covered peptide substances to its list of bulk drug substances eligible for compounding under federal law, Celularity and Vesalius intend to supply qualifying Peptual-branded APIs to appropriately licensed U.S. compounding pharmacies. That conditional pathway shapes the compliance architecture being built now: lot-level traceability, verified sourcing, and documented analytical testing are the prerequisites for any future compounding-eligible supply chain. GLP-1 receptor agonists and other weight-loss peptides are explicitly excluded from the collaboration's scope.

For QA directors and supply-chain leads, the FDA's concurrent guidance urging compounding pharmacies to verify ingredient suppliers, confirm testing performed, and identify the original API manufacturer sets a clear documentation standard. A domestic finish-manufacturing arrangement with full chain-of-custody records directly addresses that verification burden, reducing the due-diligence exposure that pharmacies currently carry when sourcing from unverified foreign suppliers.

Celularity's move also reflects a broader supply-chain resilience argument that regulators have signaled repeatedly: provenance uncertainty in imported pharmaceutical ingredients carries both quality and national health-preparedness risk. Bringing downstream purification and release testing onshore narrows that gap without requiring full vertical integration of bulk synthesis.

The measurable checkpoint for this collaboration will be whether Celularity's peptide-specific manufacturing processes achieve cGMP qualification ahead of any FDA rulemaking that formalises compounding eligibility for covered peptide substances.

Source: Celularity Inc. via Business Wire, 29 October 2026.